STD Research

Dr. Stanley Lewis Q & A

Dr. Stanley Lewis is the Vice President and Chief Medical Officer for TaiMed Biologics, Inc., managing the company’s clinical development pipeline, which primarily focuses on infectious disease. Before joining TaiMed, Dr. Lewis served as a Medical Director at Genentech Inc., assisting in the out-licensing of Ibalizumab, a first-in-class monoclonal antibody viral entry inhibitor for the treatment of HIV/AIDS.
SafePositive sat down with Dr. Stanley Lewis, a trailblazer in the use of antibodies in clinical HIV/AIDS research, to discuss how these scientific findings might translate into products to prevent or treat HIV disease.  Read More>>